OBJECTIVE: To determine (i) the relationship between prescriptions for proton pump inhibitors (PPIs) and upper gastrointestinal conditions, and (ii) compliance with Pharmaceutical Benefits Scheme (PBS) prescribing guidelines for PPIs. DESIGN: Drug utilisation evaluation. SETTING: 800-bed metropolitan teaching hospital. PARTICIPANTS: 253 patients dispensed PPIs from the hospital pharmacy over five consecutive weeks (11 January to 15 February 1999). MAIN OUTCOME MEASURES: Recorded gastrointestinal conditions; previous trial of H2-antagonist therapy; compliance with PBS criteria for prescribing PPIs. RESULTS: Seventy patients (27.7%) had no appropriate upper gastrointestinal tract investigations, and 62 patients (24%) did not receive an adequate trial of H2-antagonist therapy before the commencement of a PPI. The major indications for use of PPIs in investigated patients were gastro-oesophageal reflux in 99 (54%) and peptic ulcer disease in 30 (16.4%). In only 57 patients (22.5%) did PPI prescriptions comply with PBS prescribing guidelines. Clinical indications that failed to meet prescribing criteria included milder forms of gastro-oesophageal reflux, gastritis/duodenitis, and non-specific dyspepsia with normal endoscopy results. CONCLUSION: Drug utilisation data indicate widespread use of PPIs outside current prescribing guidelines. Many patients have not had relevant investigations and/or an adequate trial of H2-antagonist therapy. These findings explain the considerable hospital expenditure on PPIs.
OBJECTIVE: To determine (i) the relationship between prescriptions for proton pump inhibitors (PPIs) and upper gastrointestinal conditions, and (ii) compliance with Pharmaceutical Benefits Scheme (PBS) prescribing guidelines for PPIs. DESIGN: Drug utilisation evaluation. SETTING: 800-bed metropolitan teaching hospital. PARTICIPANTS: 253 patients dispensed PPIs from the hospital pharmacy over five consecutive weeks (11 January to 15 February 1999). MAIN OUTCOME MEASURES: Recorded gastrointestinal conditions; previous trial of H2-antagonist therapy; compliance with PBS criteria for prescribing PPIs. RESULTS: Seventy patients (27.7%) had no appropriate upper gastrointestinal tract investigations, and 62 patients (24%) did not receive an adequate trial of H2-antagonist therapy before the commencement of a PPI. The major indications for use of PPIs in investigated patients were gastro-oesophageal reflux in 99 (54%) and peptic ulcer disease in 30 (16.4%). In only 57 patients (22.5%) did PPI prescriptions comply with PBS prescribing guidelines. Clinical indications that failed to meet prescribing criteria included milder forms of gastro-oesophageal reflux, gastritis/duodenitis, and non-specific dyspepsia with normal endoscopy results. CONCLUSION: Drug utilisation data indicate widespread use of PPIs outside current prescribing guidelines. Many patients have not had relevant investigations and/or an adequate trial of H2-antagonist therapy. These findings explain the considerable hospital expenditure on PPIs.
Authors: Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett Journal: Postgrad Med J Date: 2007-01 Impact factor: 2.401
Authors: Barbara Farrell; Kevin Pottie; Wade Thompson; Taline Boghossian; Lisa Pizzola; Farah Joy Rashid; Carlos Rojas-Fernandez; Kate Walsh; Vivian Welch; Paul Moayyedi Journal: Can Fam Physician Date: 2017-05 Impact factor: 3.275
Authors: Hojjat Salmasian; Daniel E Freedberg; Julian A Abrams; Carol Friedman Journal: Pharmacoepidemiol Drug Saf Date: 2012-12-12 Impact factor: 2.890
Authors: Laura E Targownik; Lisa M Lix; Colleen J Metge; Heather J Prior; Stella Leung; William D Leslie Journal: CMAJ Date: 2008-08-12 Impact factor: 8.262
Authors: Fermín Mearin; Julio Ponce; Marta Ponce; Agustín Balboa; Miguel A González; Javier Zapardiel Journal: World J Gastroenterol Date: 2012-09-21 Impact factor: 5.742